Medical picture archiving computer systems PACS

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

FABP5-IN-1 is a selective and high affinity fatty acid binding protein 5 (FABP5) inhibitor with a K i value of 1.7 μM, and does not bind to both FABP3 and FABP7. FABP5-IN-1 shows potent antinociceptive effectsIn VivoFABP5-IN-1 (Compounds 4j: 20

DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation.

DS-3801b is a potent and non-macrolide agonist of GPR38. DS-3801b is expected to be novel gastrointestinal prokinetic agents for the research of functional gastrointestinal disorders such as gastroparesis and chronic constipation.

sargramostim.

sargramostim.

Psma-hbed-CC.

Psma-hbed-CC.

NVP-SAA164.